SAN DIEGO, June 1, 2020 /PRNewswire/ -- DelMar
Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the
"Company"), a biopharmaceutical company focused on the development
of new solid tumor cancer therapies, today announced that two
posters updating results from the company's two Phase 2 clinical
trials of VAL-083 will be presented at the 2020 American
Association for Cancer Research Virtual Annual Meeting II to be
held June 22-24, 2020.
Details regarding the posters to be presented in the Phase 2
Trials in Progress session are as follows:
Title: "Phase 2 trial of dianhydrogalactitol
(VAL-083) in patients with newly diagnosed MGMT-unmethylated
glioblastoma"
Lead Author: Dr. Zhong-Ping
Chen, Sun Yat-sen University Cancer Center
Poster Number: CT273
Summary: This poster will include data from the company's
ongoing Phase 2 trial of VAL-083 being conducted at Sun Yat-sen
University Cancer Center as a first line therapy, and includes
updates on enrollment, safety and efficacy.
Title: "Phase 2 study of dianhydrogalactitol
(VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve
glioblastoma in the recurrent or adjuvant setting"
Lead Author: Dr. Barbara
O'Brien, M.D. Anderson Cancer Center
Poster Number: CT272
Summary: This poster will include data from the company's
ongoing Phase 2 trial of VAL-083 being conducted at M.D. Anderson
Cancer Center as a treatment in the recurrent and adjuvant
settings, and includes updates on enrollment, safety and
efficacy.
Additional posters relevant to VAL-083 to be available from the
conference include:
Session: Mechanisms of DNA Damaging
Therapeutics
Title: "Dianhydrogalactitol (VAL-083) synergizes with
topoisomerase inhibitors to overcome homologous recombination
repair activity in glioblastoma and prostate cancer cells"
Poster Number: 1369
Session: DNA-reactive Agents and Other
Title: "Dianhydrogalactitol (VAL-083) exhibits strong
efficacy in GBM tumors with different (epi)genetic background and
treatment history"
Poster Number: 5231
All abstracts can be accessed via
https://www.abstractsonline.com/pp8/#!/9045.
About VAL-083
VAL-083 (dianhydrogalactitol) is a
"first-in-class", bifunctional DNA-targeting agent that introduces
inter-strand DNA cross-links at the N7-position of guanine leading
to DNA double-strand breaks and cancer cell death. VAL-083 has
demonstrated clinical activity against a range of cancers including
GBM and ovarian cancer in historical clinical trials sponsored by
the U.S. National Cancer Institute (NCI). DelMar has demonstrated
that VAL-083's anti-tumor activity is unaffected by common
mechanisms of chemoresistance, including MGMT, in cancer cell
models and animal studies. Further details regarding these
studies can be found at:
http://www.delmarpharma.com/scientific-publications.html.
About DelMar Pharmaceuticals, Inc.
Located in San Diego,
California, DelMar is focused on the development and
commercialization of new therapies for cancer patients who have
limited or no treatment options. By focusing on understanding tumor
biology and mechanisms of treatment resistance, the Company
identifies biomarkers to personalize new therapies in indications
where patients are failing, or are unable to tolerate,
standard-of-care treatments.
The Company's current pipeline is based around VAL-083, a
"first-in-class", small-molecule chemotherapeutic with a novel
mechanism of action that has demonstrated clinical activity against
a range of cancers, including central nervous system, ovarian and
other solid tumors (e.g. NSCLC, bladder cancer, head and neck) in
U.S. clinical trials sponsored by the NCI. Based on DelMar's
internal research programs and these prior NCI-sponsored clinical
studies, the Company is conducting clinical trials to support the
development and commercialization of VAL-083 to solve significant
unmet medical needs.
VAL-083 is being studied in two collaborator-supported,
biomarker-driven Phase 2 clinical trials for MGMT-unmethylated GBM.
Overcoming MGMT-mediated resistance represents a significant unmet
medical need in the treatment of GBM. In addition, DelMar has
announced the allowance of a separate IND for VAL-083 as a
potential treatment for platinum-resistant ovarian cancer.
Further information on DelMar's clinical trials can be found on
clinicaltrials.gov:
https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs.
For additional information, please visit http://delmarpharma.com/;
or contact DelMar Pharmaceuticals Investor Relations:
ir@delmarpharma.com / (604) 629-5989.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995, including statements regarding the status of the
Company's clinical trials, the reporting of the results, and the
impact of the COVID-19 pandemic. . Any forward-looking
statements contained herein are based on current expectations but
are subject to a number of risks and uncertainties. The
factors that could cause actual future results to differ materially
from current expectations include, but are not limited to, risks
and uncertainties relating to the impact of the COVID-19 pandemic
on the Company's operations and clinical trials, the Company's
ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the availability of substantial additional
funding for the Company to continue its operations and to conduct
research and development, clinical studies and future product
commercialization; and, the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in the Company's filings with the SEC,
including the Company's Annual Report on Form 10-K for the year
ended June 30, 2019, the Company's
Quarterly Reports on Form 10-Q, and the Company's Current Reports
on Form 8-K.
CONTACTS:
Investors:
CORE IR
516-222-2560
ir@coreir.com
Media:
Jules
Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-present-updates-of-two-phase-2-clinical-trials-of-val-083-at-the-2020-american-association-for-cancer-research-virtual-annual-meeting-ii-301068192.html
SOURCE DelMar Pharmaceuticals, Inc.
